Boston Scientific Acquires Xlumena

Boston Scientific To Acquire Penumbra, Inc. for About $14.5 Billion

January 16, 2026

Medical Devices

Boston Scientific signed a definitive agreement to acquire Penumbra, Inc. in a cash-and-stock transaction valued at about $14.5 billion on an enterprise value basis. The deal is designed to broaden Boston Scientific’s vascular and neurovascular portfolio, particularly in mechanical thrombectomy and adjacent neurovascular markets, with expected closing in 2026 subject to regulatory approvals and Penumbra shareholder approval.

Boston Scientific Acquires Valencia Technologies

January 12, 2026

Medical Devices

Boston Scientific acquired Valencia Technologies to advance its urology and pelvic health portfolio, adding Valencia’s implantable tibial nerve stimulation technology. The deal is expected to close in the first half of 2026, with financial terms undisclosed.

Boston Scientific Acquires Axonics, Inc.

November 15, 2024

Medical Devices

Boston Scientific agreed to acquire Axonics, a medical technology company focused on urinary and bowel dysfunction, for $71 per share in cash, valuing the equity at approximately $3.7 billion. The boards approved the transaction, which was expected to close in the first half of 2024, and Boston Scientific later announced the acquisition closed on November 15, 2024.

Caldera Medical Acquires UVision 360 and the LUMINELLE Product Family

October 8, 2024

Medical Devices

Caldera Medical has acquired UVision 360, the developer of the LUMINELLE hysteroscopy and cystoscopy systems, expanding its minimally invasive women's health device portfolio. The deal brings the LUMINELLE product family — including the new LUMINELLE Bx on-demand biopsy technology — into Caldera's commercial infrastructure to broaden office-based and surgical hysteroscopy capabilities.

Boston Scientific Acquires Lumenis Surgical Business from Baring Private Equity Asia for $1.07B

March 3, 2021

Medical Devices

Boston Scientific has agreed to acquire the Lumenis Surgical Business from Baring Private Equity Asia/Lumenis for USD 1.07 billion, subject to closing adjustments. The deal transfers Lumenis' surgical laser portfolio and global surgical team (including its Israeli laser center of excellence) to Boston Scientific to bolster its Urology strategy, while Lumenis — still owned by BPEA — will focus on Aesthetics and Vision.

Astellas Pharma Acquires Xyphos Biosciences

December 26, 2019

Biotechnology

Astellas Pharma has acquired Xyphos Biosciences, gaining Xyphos' ACCEL convertible-CAR technology platform and immuno-oncology talent. The deal included $120 million paid at closing and potential milestone payments bringing the total transaction value to up to $665 million.